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ABSTRACT
The anti-proliferative effects of histone deacetylase
(HDAC) inhibitors and 1a,25-dihydroxyvitamin D3
[1a,25(OH)2D3] converge via the interaction of un-
liganded vitamin D receptor (VDR) with co-repres-
sors recruiting multiprotein complexes containing
HDACs and via the induction of cyclin-dependent
kinase inhibitor (CDKI) genes of the INK4 and Cip/
Kip family. We investigated the effects of the HDAC
inhibitor Trichostatin A (TSA) and 1a,25(OH)2D3 on
the proliferation and CDKI gene expression in
malignant and non-malignant mammary epithelial
cell lines. TSA induced the INK4-family genes p18
and p19, whereas the Cip/Kip family gene p21
was stimulated by 1a,25(OH)2D3. Chromatin immu-
noprecipitation and RNA inhibition assays
showed that the co-repressor NCoR1 and some
HDAC family members complexed un-liganded VDR
and repressed the basal level of CDKI genes,
but their role in regulating CDKI gene expression
by TSA and 1a,25(OH)2D3 were contrary. HDAC3 and
HDAC7 attenuated 1a,25(OH)2D3-dependent induc-
tion of the p21 gene, for which NCoR1 is essential. In
contrast, TSA-mediated induction of the p18 gene
was dependent on HDAC3 and HDAC4, but was
opposed by NCoR1 and un-liganded VDR. This
suggests that the attenuation of the response to
TSA by NCoR1 or that to 1a,25(OH)2D3 by HDACs
can be overcome by their combined application
achieving maximal induction of anti-proliferative
target genes.
INTRODUCTION
The classical role of histone deacetylases (HDACs) is to
reduce transcription by the removal of acetyl groups from
histones, a process that makes the DNA bind to the
histones more tightly (1). The mammalian HDAC gene
family is categorized into three classes (2). Class I includes
HDACs 1, 2, 3 and 8 and class II HDACs 4, 5, 6, 7, 9 and
10. HDAC11 shares characters of both classes I and II.
Class I HDACs are ubiquitously expressed and have
general roles in homeostasis, signal transduction, cell cycle
control and cancer development (3). HDAC3 is tightly
linked to gene regulation by nuclear receptors through its
functional connection to co-repressors. This HDAC also
has a transcription-independent role in mitosis as well as
functions in cell cycle progression and stem cell renewal
(3,4). Class II HDACs, namely HDACs 4, 5, 7 and 9,
are expressed tissue-speciﬁcally and shuttle between
the nucleus and the cytoplasm in a stimulus-dependent
manner (5). HDAC7 suppresses apoptosis in thymocytes
via the orphan nuclear receptor Nurr77 (6). HDAC6 is the
only HDAC identiﬁed to deactylate tubulin and this
capacity is required for its function in aggrosomes,
through which it aﬀects the disposal of misfolded proteins
(7). All class I and II HDACs are sensitive to the inhibitor
Trichostatin A (TSA) (8). In contrast, the members of the
third HDAC class, SIRT1 to 7, are TSA insensitive.
Although the roles of individual HDACs in cancer are
unsolved, HDAC inhibitors are of interest to the medical
community because they have been shown in numerous
experiments to reduce cancer cell growth and enhance cell
diﬀerentiation. They are thought to exert this eﬀect by
eﬀecting changes in the gene expression of the cyclin-
dependent kinase inhibitor (CDKI) genes p18, p19 and p21
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accumulation of acetylated histones on the p21 promoter,
whereas on the CDKI gene p27 no change was observed
(10,13).
The cell cycle transition between the ﬁrst gap phase (G1)
to DNA synthesis phase (S) is co-operatively regulated by
several classes of cyclin-dependent kinases (CDKs). CDKs
hyperphosphorylate the retinoblastoma protein, which
then releases E2F family transcription factors needed for
the entry into the S phase. CDKs activities are turned oﬀ
by CDKI proteins. CDKIs are a group of low molecular
weight proteins that associate with cyclin–CDK com-
plexes or CDKs alone and inhibit their activity. Most
tumors carry mutations or epigenetic malfunctions in
regulators of CDKs, but not in CDKs themselves. In
cancer treatment this common misregulation of CDK
regulators has not yet been successfully targeted in clinical
trails (14). The INK4 subfamily of CDKIs includes closely
related genes p15 (INK4B or CDKN2B), p16 (INK4A or
CDKN2A), p14 (ARF, also transcribed from CDKN2A),
p18 (INK4C or CDKN2C) and p19 (INK4D or CDKN2D).
The protein products of this gene family speciﬁcally bind
and inhibit CDK4 and CDK6, which prevent cyclin
D-dependent phosphorylation of the retinoblastoma
protein (15,16). The CDKIs p21 (WAF1/Cip1 or
CDKN1A), p27 (Kip1 or CDKN1B) and p57 (Kip2 or
CDKN1C) belong to the CIP/KIP family. They selectively
inhibit the association of cyclin A, D and E with CDK
complexes and thus control the G1 to S phase transition in
the mammalian cell cycle. We recently demonstrated three
functional vitamin D receptor (VDR)-associated regions
on the p21 promoter in vivo (17). Vitamin D response
elements are positioned at 2.3kB, 4.5kB and 6.9kB
from the transcription start site (TSS) of the p21 gene with
p53 binding co-localized in two of these regions.
Concomitantly, p21 has been shown to be one of the key
genes for anti-proliferative action of 1a,25-dihydroxyvita-
min D3 [1a,25(OH)2D3] (18). In contrast, p27 is a short-
lived protein and its activity is regulated almost exclusively
post-translationally by the ubiquitin–proteosome protein
degradation system. Decreased p27 protein levels are
common in many tumor types (19).
VDR is a member of the nuclear receptor superfamily
and acts as a transcription factor by binding to speciﬁc
response elements in its target genes. In the absence of
ligand, VDR associates via co-repressor proteins, such as
NCoR1 and SMRT/NCoR2, with HDACs (20). This
complex represses gene transcription by stabilizing DNA–
histone contact and closing chromatin structure. The
natural VDR ligand 1a,25(OH)2D3 has an essential role in
calcium homeostasis and skeletal integrity (21), but also
an important role in the regulation of cell growth and
diﬀerentiation (22). The ligand binds the VDR with high
aﬃnity, changes the conformation of its ligand-binding
domain, so that it is more favorable for the binding of co-
activator proteins (23) after the co-repressor/HDAC
complex has dissociated.
By combining diﬀerent therapeutic compounds, that
target transcription of genes, it might be possible to
sensitize cancer cells to particular chemotherapies.
Therefore, in this study we investigated the eﬀects
of TSA and 1a,25(OH)2D3 on the proliferation and
CDKI gene expression in malignant and non-malignant
mammary epithelial cell lines. TSA induced the genes
p18 and p19, whereas the p21 gene was stimulated
by 1a,25(OH)2D3. Chromatin immuno-precipitation
(ChIP) and RNA inhibition (RNAi) assays showed that
NCoR1 and certain HDAC family members complexed
un-liganded VDR and repressed the basal level of CDKI
genes, but their role in regulating CDKI gene expression
by 1a,25(OH)2D3 and TSA were contrary. HDAC3 and
HDAC7 attenuated 1a,25(OH)2D3-dependent induction
of p21, for which NCoR1 is essential. TSA-mediated
induction was dependent on HDAC3 and HDAC4,
but was opposed by NCoR1 and un-liganded VDR.
This suggests that the attenuation of the response to
1a,25(OH)2D3 by HDACs or the response to TSA by
NCoR1 can be overcome by their combined application
achieving maximal induction of anti-proliferative target
genes.
MATERIALS AND METHODS
Cell culture
MCF-12A (spontaneously immortalized mammary epithe-
lial) cells were cultured in a mixture of DMEM and Ham’s
F12 medium (1:1) with 20ng/ml of epidermal growth
factor, 100ng/ml of cholera toxin, 10mg/ml insulin,
500ng/ml hydrocortisone and 5% horse serum. MCF-7
(mammary epithelial adenocarcinoma) cells were grown in
a-MEM supplemented with 7% fetal bovine serum (FBS).
MDA-MB453 (mammary epithelial metastatic carcinoma)
cells were grown in a-MEM supplemented with 10% FBS.
All cell lines were grown in a humidiﬁed 95% air/5%
CO2 incubator. Before mRNA extraction or ChIP assay,
MCF-7 and MDA-MB453 cells were grown overnight in
phenol red free DMEM with 5% charcoal-stripped FBS
and MCF-12A in above-mentioned culture medium but
with 5% charcoal-stripped FBS instead of horse serum.
The cells were treated at a density of 50–60% conﬂuency
for indicated time periods with 15nM TSA (Sigma
Aldrich, diluted in EtOH) and/or 10nM 1a,25(OH)2D3
(kindly provided by Dr Lise Binderup, LEO Pharma,
Ballerup, Denmark, diluted in EtOH) or EtOH (0.1%).
Proliferation, cell cycle and cell growth analysis
Cell proliferation levels were studied by 5-bromo-2-
deoxyuridine (BrdU) incorporation. For measuring rela-
tive proliferation levels the Cell Proliferation ELISA kit
(Roche) was used as instructed by the manufacturer. Cell
cycle analysis was performed by propidium iodide DNA
staining. Fixation and staining of the cells were performed
according to standard protocols. Brieﬂy, after 48h
incubation with ligands or vehicle cells were harvested
by trypsinization and ﬁxed with ice-cold 70% EtOH.
After overnight incubation at 48C, cells were centrifuged
and incubated in 1ml RNAase A solution (150mg/ml
RNAase A in phosphate-buﬀered saline (PBS, 140mM
NaCl, 2.7mM KCl, 1.5mM KH2PO4, 8.1mM
Na2HPO4.2H2O)) for 1h at 508C. Propidium iodide in
PBS was added to the ﬁnal concentration of 8mg/ml and
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portion of the cells in the diﬀerent phases of the cell cycle,
DNA content of cells was analyzed using a FACSCanto II
ﬂow cytometer with BD FACSDiva Flow Cytometry
Software Version 5.0. (Becton Dickinson, Mountain View,
CA, USA). For growth analysis, cells were cultured for
5 days in the presence of either vehicle or ligands.
Cell numbers were counted using a haemacytometer
after the cells had been trypsinized, suspended in PBS
supplemented with 5% FBS and stained with the vital dye
erythrosine-red.
RNA extraction and real-time quantitative PCR
Total RNA was extracted using the Mini RNA Isolation
II kit (Zymo Research, HiSS Diagnostics, Freiburg,
Germany) and cDNA synthesis was performed for 1h at
378C using 1mg of total RNA as a template, 100 pmol
oligodT15 primer and 40 U reverse transcriptase
(Fermentas, Vilnius, Lithuania). Real-time quantitative
PCR was performed in an IQ-cycler (BioRad, Hercules,
CA, USA) using the dye SybrGreen I (Molecular Probes,
Leiden, The Netherlands). Fast Start Taq polymerase
(Roche) and 3mM MgCl2 were used and the PCR cycling
conditions were: 40 cycles of 30s at 958C, 30s at 608C and
30s at 728C. The sequences of the gene-speciﬁc primer
pairs for the human CDKI genes p18, p19, p21 and p27
and the control gene acidic riboprotein P0 (RPLP0)
are listed in the Table S1. Fold inductions were calcu-
lated using the formula 2
(Ct), where Ct is the
Ct(stimulant)Ct(EtOH), Ct is Ct(CDKI)Ct(RPLP0) and
Ct is the cycle at which the threshold is crossed. Basal
expression levels were calculated using the formula
2
(Ct). Quality of the PCR product was monitored
using post-PCR melt curve analysis.
ChIP assay. ChIP and re-ChIP were performed as
described previously (17), except that formaldehyde
cross-linking time was diminished to 5min and antibodies
were used against HDAC1 (sc-6298), HDAC2 (sc-6296),
HDAC3 (sc-11417), HDAC4 (sc-11418), HDAC5 (sc-
11419), HDAC6 (sc-11420), HDAC7 (sc-11421), VDR (sc-
1008) NCoR1 (sc-8994) and RNA polymerase II (Pol II)
(sc-899) and normal mouse IgG (sc-2027) as a control (all
obtained from Santa Cruz Biotechnologies, Heidelberg,
Germany). The anti-acetylated histone 4 (AcH4) and anti-
acetylated histone 3, lysine 14 (AcH3-K14) antibodies
were obtained from Upstate (Lake Placid, NY, USA).
PCR of chromatintemplates
For each of the three VDR-associated regions of the p21
promoter as well as for the TSS regions of all four CDKI
genes, speciﬁc primer pairs were designed (Table S2),
optimized and controlled by running PCR reactions with
25ng genomic DNA (input) as a template. When running
immuno-precipitated DNA (output) as a template, the
following PCR proﬁle was used: pre-incubation for 5min
at 958C, 40 cycles of 30s at 958C, 30s at the primer-
speciﬁc temperature (Table S2) and 30s at 728C and one
ﬁnal incubation for 10min at 728C. The PCR products
were separated by electrophoresis through 2% agarose
gels. Relative acetylation levels were calculated using
the formula 2
(Ct) where Ct is Ct(output)Ct(input) and
normalized by the amount of chromatin used for
preparation of input versus output. Gel images were
scanned on a FLA3000 reader (Fuji) using ScienceLab99
software (Fuji).
Chromatin conformation capture (C3)analysis
Chromatin was cross-linked and lysed as for ChIP assays
but the sonication was reduced to 2 pulses. After removal
of cellular debris by centrifugation, 100ml of chromatin
diluted in 345ml of ChIP dilution buﬀer was digested
overnight at 378C with the restriction enzymes MvaI
(50 units), Hpy8I (25 units) or SchI (25 units). Digested
chromatin was ligated with 50 U T4 DNA ligase
(Fermentas) for 2h at 168C and then 2ml of proteinase
K (10mg/ml, Fermentas) was added and the samples were
further incubated overnight at 648C. Finally, the DNA
was recovered by phenol–chloroform extraction followed
by EtOH precipitation and analyzed by PCR using
primers which are listed in Table S3. As positive controls,
plasmids covering the p21 promoter regions 7930 to
6072, 4968 to 3818 or 2620 to 1335 were digested
and ligated with plasmid covering the TSS region (676
to +535).
siRNA inhibition
Cells were grown to 30–40% conﬂuency. MCF-12A cells
were transfected using Lipofectamine 2000 (Invitrogen)
and MCF-7 and MDA-MB453 cells with Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s
instructions. Double-stranded siRNA oligonucleotides
(Eurogentec, 200 pmol of each siRNA, for sequences see
Table S4) were transfected for 5h, then charcoal-stripped
FBS was added (5% ﬁnal concentration) and the
transfection was continued for 48h. Cell treatments,
RNA extractions and real-time quantitative PCR were
carried out as described above.
RESULTS
Anti-proliferative effects ofTSA and 1a,25(OH)2D3
inbreast epithelial cells
We have chosen three breast epithelial cell lines
MCF-12A, MCF-7 and MDA-MB453 as models for
testing anti-proliferative and gene regulatory eﬀects of
TSA and 1a,25(OH)2D3. MCF-12A is a spontaneously
immortalized cell line, MCF-7 is an estrogen-responsive
adenocarcinoma cell line and MDA-MB453 is an
estrogen-insensitive metastatic carcinoma cell line. All
three cell lines were treated with the relative low doses of
15nM TSA and 10nM 1a,25(OH)2D3, alone and in
combination, for ﬁve days (Figure 1A). Relative prolifera-
tion in reference to EtOH-treated cells was then measured
by BrdU incorporation. TSA showed a signiﬁcant anti-
proliferative eﬀect only in MCF-7 cells (32% reduction),
while 1a,25(OH)2D3 inhibited the growth of MCF-12A,
MCF-7 and MDA-MB453 cells by 40, 34 and 42%,
respectively. The combinatorial treatment with TSA and
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approximately 50% reduced growth compared to EtOH-
treated cells. At the example of MCF-7 cells the results of
the proliferation tests were conﬁrmed by cell growth
analysis (Figure S1). After three days treatment with the
combination of TSA and 1a,25(OH)2D3 there were 60%
fewer cells than in the vehicle control. At day 5, the
combination treatment also inhibited cell growth signiﬁ-
cantly compared to either 1a,25(OH)2D3 or TSA treat-
ment alone. Both single 5-day-treatments also decreased
cell number signiﬁcantly (75% and 68%) compared to
cells treated with vehicle.
To determine, if the lack of proliferation was a result of
a block in the cell cycle progression, the three cell lines
were treated for two days with ligands and subsequently
stained by propidium iodide followed by ﬂuorescence-
activated cell sorting (FACS) (Figure 1B). A treatment
with TSA alone showed no signiﬁcant eﬀect on the
portion of the cell cycle phase distribution, although we
observed a decrease of MCF-7 cells in the S phase and of
MDA-MB453 cells in the G1/G0 phase. In contrast,
1a,25(OH)2D3 treatment provided a signiﬁcant increase of
MCF-7 and MDA-MB453 cells in the G1/G0 phase and
a decrease in G2/M phase. In addition, in MCF-7 cells,
a signiﬁcant decrease of cells in the S phase was also
observed after 1a,25(OH)2D3 treatment. Interestingly, in
the latter cells, the combined treatment with TSA and
1a,25(OH)2D3 showed an increase of cells in the G1/G0
phase and a decrease in the S and G2/M phase. The eﬀects
in MCF-7 cells were signiﬁcant, not only compared to the
vehicle control, but also in reference to the single
stimulations with TSA and 1a,25(OH)2D3. In MCF-12A
and MDA-MB453 cells the combined treatment resulted
only in a signiﬁcant increase of cells in G1/G0 phase.
FACS analysis also indicated that the number of
apoptotic cells did not change under any stimulation
(data not shown) suggesting that in our model cell lines
the induction of programmed cell death was not respon-
sible for our results.
Taken together, concerning anti-proliferative eﬀects, via
an arrest in the G1/G0 phase, the treatment with TSA and
1a,25(OH)2D3, alone and in combination, was most
eﬃcient in MCF-7 cells. However, 1a,25(OH)2D3 had
also signiﬁcant anti-proliferative eﬀects in MCF-12A and
MDA-MB453 cells.
CDKI gene TSSacetylation and HDAC bindingin
response toTSA and 1a,25(OH)2D3
The basal mRNA expression levels of the four CDKI
genes p18, p19, p21 and p27 were monitored by real-time
quantitative PCR in relation to the control gene RPLP0 in
MCF-12A, MCF-7 and MDA-MB453 cells (Figure S2A).
The three remaining CDKI gene family members, p15, p16
and p57, were not expressed to detectable level in all of
these cell lines (data not shown) and hence were excluded
from further analysis. The genes p18 and p21 had the
highest basal expression in non-cancerous MCF-12A cells,
whereas most p19 mRNA expression was found in
malignant MDA-MB453 cells. The genes p18 and p19
were expressed lowest in p53
+ MCF-7 cells, whereas the
lowest basal mRNA levels of the p21 gene were detected
in p53
 MDA-MB453 cells. In contrast, basal p27
mRNA expression was not signiﬁcantly diﬀerent in the
three cell lines.
The acetylation levels of histone H3-K14 and histone
H4 on the TSS regions of the genes p18, p19, p21 and p27
in response to 1h treatment with TSA and 1a,25(OH)2D3
were studied by ChIP assays in all three cell lines
(Figure 2A). In parallel, the mRNA induction of the
four genes over time in response to these ligands was
studied by real-time PCR (time point 3h in Figure 2B,
time points 1, 2, 4 and 6h in Figure S2B). In general, the
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Figure 1. TSA and 1a,25(OH)2D3 inhibit the growth of epithelial breast cancer cells. (A) MCF-12A, MCF-7 and MDA-MB453 cells were treated,
alone or in combination, with 15nM TSA, 10nM 1a,25(OH)2D3 and EtOH every second day for 5 days in total. Cell proliferation levels were
measured by BrdU incorporation using a Cell Proliferation ELISA. (B) The portion of the cells in the diﬀerent phases of the cell cycle were
determined after 48h ligand treatment by propidium iodide DNA staining using FACSCanto II ﬂow cytometer analysis. Columns indicate the means
of at least three independent cell treatments and the bars represent standard deviations (A and B). A two-tailed Student’s t-test was performed
to determine the signiﬁcance of the stimulation in reference to vehicle-treated control (
P<0.05;
P<0.01;
P<0.001). The signiﬁcance of the
co-treatment in comparison to the single stimulations with TSA and 1a,25(OH)2D3 were calculated (red stars).
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Figure 2. Acetylation and HDAC binding to the TSS regions of CDKI genes. (A) Chromatin was extracted from MCF-12A, MCF-7 and MDA-
MB453 cells that had been treated, alone or in combination, with 15nM TSA, 10nM 1a,25(OH)2D3 and EtOH for 1h and fold inductions were
calculated in reference to vehicle control. Acetylation of the TSS of the genes p18, p19, p21 and p27 was analyzed by ChIP assays using anti-AcH3-
K14 and anti-AcH4 antibodies, where IgG served as speciﬁcity control. The acetylation levels relative to input were determined by quantitative real-
time PCR. IgG precipitation was subtracted from quantiﬁed acetylation levels. (B) After 3h of ligand treatment the mRNA expression of the four
CDKI genes relative to the control gene RPLP0 was determined by real-time quantitative PCR and fold inductions were calculated in reference to
vehicle control. Columns indicate the means of at least three independent cell treatments and the bars represent standard deviations. A two-tailed
Student’s t-test was performed to determine the signiﬁcance of the stimulation in reference to vehicle-treated control (
P<0.05;
P<0.01;
P<0.001). The signiﬁcance of the co-treatment in comparison to the single stimulations with TSA and 1a,25(OH)2D3 were calculated (red stars).
(C) The binding of HDACs 1–7 and of NCoR1 to the TSS of the four CDKI genes in non-treated cells was determined by ChIP assays using the
respective speciﬁc antibodies. (D) Re-ChIP experiments were performed on the same regions on chromatin that was extracted from MDA-MB453
cells being treated, alone or in combination, with 15nM TSA, 10nM 1a,25(OH)2D3 and vehicle (EtOH) for 1h. Precipitations with IgG served
as speciﬁcity controls (C and D). Representative agarose gels of the PCR products are shown.
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highest in MCF-12A cells (please note the diﬀerent scales
in Figure 2A). TSA induced the expression of p18 and p19
mRNA (11- and 6-fold at 4h) in MCF-7 cells and of p18
in MCF-12A cells (Figures 2B and S2B). Comparable
eﬀects were observed also concerning the acetylation levels
of the p18- and p19-TSS regions (2-fold for AcH3-K14
and 4-fold for AcH4 in MCF-7 cells). In MCF-12A cells,
only the AcH4 level on the p18-TSS was signiﬁcantly
induced (10.8-fold). Even in MDA-MB453 cells the AcH4
level on the p18-TSS was induced, but this eﬀect was not
transmitted to signiﬁcant mRNA inductions before 6h of
treatment. Expression of p18 was induced also in MDA-
MB453 cells, when higher (100nM) TSA concentration
was used, but with this concentration, all combinatorial
eﬀects with 1a,25(OH)2D3 were lost (data not shown).
In contrast, p21 and p27 mRNA expression was not
signiﬁcantly induced by TSA. Acetylation of the p27-TSS
was even repressed by TSA, while p21-TSS acetylation
was induced, but without transmitting this eﬀect into
induction of p21 gene transcription.
In all three cell lines the known 1a,25(OH)2D3 target
gene p21 (17,24) was signiﬁcantly induced by
1a,25(OH)2D3 (1.6- to 3.6-fold). Additionally, in MCF-
12A and MDA-MB453 cells the p18 gene (1.9- and
1.6-fold), in MCF-7 and MDA-MB453 cells the p19 gene
(1.9- and 1.6-fold) and in MCF-12A and MCF-7 cells the
p27 gene (1.7- and 3.2-fold) responded to 1a,25(OH)2D3
treatment (Figures 2B and S2B). However, in most cases
these mRNA inductions were not reﬂected by changes of
the acetylation levels of the respective CDKI gene TSS
regions (Figure 2A).
In general, the combined treatment with TSA and
1a,25(OH)2D3 resulted in all three cell lines in a higher
mRNA expression than either of the substances alone (an
exception was the p27 gene in MCF-7 cells, see Figures 2B
and S2B). In a number of cases, such as the p18 gene in
MCF-12A cells, the p19 gene in MCF-12A and MCF-7
cells, the p21 gene in MCF-7 and MDA-MB453 cells and
the p27 gene in MDA-MB453 cells, these co-operative
eﬀects were also statistically signiﬁcant.
To elucidate the role of individual HDACs on acetyla-
tion changes on the TSS regions of CDKI genes, we
analyzed by ChIP assays the occupancy of the CDKI gene
TSS regions for HDAC1 to 7 and NCoR1 (Figure 2C).
The most pre-dominant deacetylase enzyme was HDAC3,
which was found in all three cell lines associated with the
TSS of the genes p18, p19 and p21, but did not bind
signiﬁcantly to the p27-TSS. NCoR1 was also widely
present at the TSS regions of all four CDKI genes in all of
cell lines. In MDA-MB453 cells, HDAC4 was also bound
to the TSS regions of all four genes. HDAC2 bound only
to the p18 and p19-TSS regions in MCF-12A cells and
HDAC5 to the p21 and p27-TSS regions in all studied cell
lines and that of the p19 gene in MCF-7 cells. In addition,
HDAC7 was present on the p18, p21 and p27-TSS regions
in MCF-7 cells.
For a more detailed analysis of the role of individual
HDAC and NCoR1 proteins in the actions of the VDR on
the TSS of the four CDKI genes, re-ChIP experiments
were performed with anti-VDR antibody in the ﬁrst
precipitation and the second precipitation with antibodies
against HDAC3, HDAC4, HDAC5, HDAC6, Pol II and
NCoR1 in MDA-MD453 cells that were treated, alone
and in combination, with TSA and 1a,25(OH)2D3 for 1h
(Figure 2D). In ChIP assays HDACs 3, 4, 5 and 7 were
found to bind the CDKI TSSs and to some extent also
to VDREs on the p21 promoter (Figures 2C and 3D,
respectively). Therefore, they were selected for reChIP
experiments with anti-VDR antibodies. The other
HDACs were left out, because they showed no or only
low binding on the studied chromatin regions. Under non-
stimulated conditions VDR was found on the p18-TSS in
a complex with HDAC3, HDAC4, HDAC5 and HDAC7.
The VDR-HDAC3 complex was resistant against stimula-
tion with 1a,25(OH)2D3 alone, while TSA induced the
dissociation of all HDACs. On this TSS TSA and
1a,25(OH)2D3 induced VDR-Pol II and VDR–NCoR1
complexes. On the p19-TSS and the p27-TSS only VDR–
HDAC3 complexes can be detected, which dissociate after
stimulation with TSA or 1a,25(OH)2D3. In contrast, on
the p21-TSS all seven proteins were found in complexes
with the VDR. VDR–HDAC3 complexes were enhanced
by 1a,25(OH)2D3 alone and VDR–HDAC6 complexes
were induced by TSA alone. Both compounds, alone
and in combination, reduced VDR–HDAC4 and
VDR–NCoR1 complexes on this TSS. The VDR–
HDAC5 complex was sensitive to treatments with TSA
and the VDR–HDAC7 complex to stimulations with
1a,25(OH)2D3. On the VDR–Pol II complex none of the
treatments had a signiﬁcant eﬀect.
In summary, TSA induced TSS acetylation and mRNA
expression of the genes p18 and p19, while 1a,25(OH)2D3-
induced p21 mRNA expression without aﬀecting the
overall acetylation status of the p21-TSS. The latter
divergence also became obvious concerning the combina-
torial eﬀects of TSA and 1a,25(OH)2D3. The most striking
diﬀerence between the CDKI gene TSS regions was the
lack of HDAC3 and NCoR1 binding to the p27-TSS,
where also histone acetylation was not induced by TSA.
Moreover, on the p18- and p21-TSS VDR formed
complexes with HDACs, Pol II and NCoR1, which were
all sensitive to either TSA, 1a,25(OH)2D3 or a combina-
torial treatment.
Chromatin looping, TSSacetylation and HDACbinding
on VDR-associated regionsof thep21 promoter
To study the eﬀects of TSA and 1a,25(OH)2D3 on the
looping to the TSS of those chromatin regions that are
known to associate with VDR in the p21 promoter (17)
we used the C3 technique (Figure 3A). MDA-MB453
cells were stimulated for 1h with the compounds and
their chromatin was cross-linked, digested with restriction
endonucleases, ligated and analyzed by PCR (Figure 3B).
Looping of 1a,25(OH)2D3 responsive regions 1 (p21-1,
located 2.3kB from the TSS, primer C), 2 (p21-2,
4.5kB, primer E) and 3 (p21-3, 7.1kB, primer G) were
studied using regions located 1.7kB (primer B), 3.1kB
(primer D) and 6.1kB (primer F) from the TSS as
negative controls. TSA alone was unable to induce any
looping of the regions of the p21 promoter, but
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Figure 3. Chromatin looping, acetylation and HDAC binding to VDR-associated regions of the p21 promoter. (A) Schematic overview on the human
p21 promoter indicating VDR and p53 binding sites described previously (17). The location of chromatin regions analyzed by ChIP assays and the
restriction enzyme recognition sites and primers used for the C3 assays are shown. (B) Chromatin was extracted from MDA-MB453 cells, which had
been treated, alone or in combination, with 15nM TSA, 10nM 1a,25(OH)2D3 and EtOH for 1h, cross-linked and digested with the enzymes MvaI,
Hpy8I and SchI. After ligation the DNA was extracted and analyzed by PCR with primer A in combination with primers B, C, D, E, F or G.
Digestions of subcloned p21 promoter fragments served as positive controls. Representative agarose gels of the PCR products are shown.
(C) Chromatin was extracted from MCF-12A, MCF-7 and MDA-MB453 cells that had been treated, alone or in combination, with 15nM TSA,
10nM 1a,25(OH)2D3 and EtOH for 1h. Acetylation of three VDR-associated regions of the p21 promoter was analyzed by ChIP assays using anti-
AcH3-K14 and anti-AcH4 antibodies, where IgG served as speciﬁcity control. The acetylation levels relative to input were determined by quantitative
real-time PCR. IgG precipitation was subtracted from quantiﬁed acetylation levels. Columns indicate the means of at least three independent cell
treatments and the bars represent standard deviations. A two-tailed Student’s t-test was performed to determine the signiﬁcance of the stimulation
in reference to vehicle-treated control (P<0.05; P<0.01; P<0.001). The signiﬁcance of the co-treatment in comparison to the single
stimulations with TSA and 1a,25(OH)2D3 were calculated (red stars). (D) The binding of HDACs 1–7 and of NCoR1 to the TSS of the four CDKI
genes in non-treated cells was determined by ChIP assays using the respective speciﬁc antibodies. (E) Re-ChIP experiments were performed on the
same regions on chromatin that was extracted from MDA-MB453 cells being treated, alone or in combination, with 15nM TSA, 10nM
1a,25(OH)2D3 and vehicle (EtOH) for 1h. Precipitations with IgG served as speciﬁcity controls (D and E). Representative agarose gels of the PCR
products are shown.
Nucleic Acids Research,2008, Vol. 36,No. 1 1271a,25(OH)2D3 stimulated the association of regions 2 and
3, but not of region 1, with the TSS. The combined
treatment with TSA and 1a,25(OH)2D3 did not show
any additional eﬀects to what was observed with
1a,25(OH)2D3 alone.
Next we studied in all three cell lines the acetylation
levels of the three VDR-associated regions of the p21
promoter (Figure 3C). Basal acetylation of these chroma-
tin regions was 8.4- and 52-fold higher in non-malignant
p53
+ MCF-12A cells than in metastatic p53 mutated
MDA-MB453 cells for H3-K14 and H4, respectively
(please note the diﬀerent scales in Figure 3C). TSA
treatment resulted in all three cell lines and on all three p21
promoter regions, except for p21-2 in MCF-12A cells, a
signiﬁcant increase of H3-K14 acetylation, whilst H4
acetylation changes were insigniﬁcant on regions 1 and 2
in MCF-12A cells, on region 1 in MCF-7 cells and on
region 3 in MDA-MB453 cells. In contrast to eﬀects on
the CDKI gene TSS regions (Figure 2A), on VDR-
associated regions of the p21 promoter, 1a,25(OH)2D3
was also able to signiﬁcantly induce histone acetylation.
AcH3-K14 was induced 2.3-fold on region 1 in MCF-12A
cells and AcH4 increased 2.3- to 4.2-fold on regions 2 and
3 in MCF-7 cells and on regions 1 and 2 in MDA-MB453
cells. The combined treatment with TSA and
1a,25(OH)2D3 followed the eﬀects of TSA alone with
the exception of region 2 in MDA-MB453 cells, where the
combination resulted in a signiﬁcantly higher H3-K14
acetylation than the individual compounds.
The occupancy of the VDR-associated regions of the
p21 promoter with HDACs and NCoR1 (Figure 3D)
diﬀered clearly from that of the CDKI TSS regions
(Figure 2C). HDAC1 was not found at all and HDAC2
only on region 1 in MCF-12A and MDA-MB453 cells.
HDAC3 was less dominant than on the TSS regions and
only bound to the p53-associated regions 1 and 2 (see
Figure 3A and (17)) in p53
+ cells (i.e. MCF-12A and
MCF-7). In MDA-MB453 cells, HDAC4 was found on all
three regions and additionally on region 2 in MCF-12A
cells. HDAC5 associated with regions 1 and 2 in MCF-
12A cells and in MCF-7 cells with regions 2 and 3.
HDAC6 was found in MCF-12A cells on region 1 and in
MDA-MB453 cells on region 2. HDAC7 associated only
with region 1 in MCF-7 and MDA-MB453 cells. Finally,
NCoR1 associated in MCF-12A cells with region 1, in
MCF-7 cells with regions 1 and 3 and in MDA-MB453
cells with region 2.
Both one-step and two-step ChIP (re-ChIP, performed
with MDA-MB 453 cells as described above for TSSs
of the CDKI genes) assays the p21 promoter regions
(Figure 3D and 3E, respectively) show that there is a
diﬀerent protein association pattern than the CDKI gene
TSS regions (Figure 2D). On region 1 of the p21 promoter,
VDR was found in complexes with HDAC4, HDAC5,
HDAC6 and HDAC7, and these complexes were sensitive
both to TSA and 1a,25(OH)2D3 treatment. Interestingly,
1a,25(OH)2D3 alone stimulated VDR–Pol II complexes
on this promoter region and co-stimulation with TSA
further enhanced this eﬀect. In the absence of stimulation
VDR was detected on region 2 in complexes with HDAC4,
HDAC7, Pol II and NCoR1. The VDR–HDAC4 and the
VDR–HDAC7 complexes were sensitive to a treatment
with both compounds, while the VDR–NCoR1 complex
dissociated only after addition of 1a,25(OH)2D3.
In contrast, the VDR–Pol II complex was enhanced by
both compounds alone and even more by the combina-
tion of them. Moreover, the combined ligand treatment
also induced the complex formation of VDR with both
HDAC3 and HDAC5 on this promoter region. In the
basal state, VDR was found on promoter region 3 in
complexes with HDAC4, HDAC6 and HDAC7. These
complexes dissociated after the addition of either of the
compounds. Interestingly, single treatments with TSA
and 1a,25(OH)2D3 stimulated the VDR–Pol II associa-
tion on this promoter region, but not their combination.
Instead, this co-treatment resulted in a VDR–NCoR1
complex forming on this region.
Taken together, 1a,25(OH)2D3 but not TSA is able
to stimulate looping of VDR-associated distal regions
2 and 3 to the TSS, suggesting that the presence of
1a,25(OH)2D3 is suﬃcient for the VDR-mediated regula-
tion of the p21 gene. The VDR-associated regions of the
p21 promoter showed, both in the modulation of their
histone acetylation as well in their basal HDAC occu-
pancy, distinct protein association proﬁles in comparison
to the TSS region. Moreover, on the three regions of the
p21 promoter VDR formed complexes with HDACs,
Pol II and NCoR1, which were sensitive to either TSA,
1a,25(OH)2D3 or a combinatorial treatment.
Modulation of CDKI basal geneactivity and ligand
responsiveness bysiRNA inhibition of VDR, NCoR1
and HDACs
Further indications on the role of VDR, NCoR1 and
HDACs 3, 4, 6 and 7 in basal expression, TSA and
1a,25(OH)2D3 inducibility of the four CDKI genes were
obtained by RNAi experiments (Figures 4, S3 and S4).
NCoR1, HDAC3 and HDAC6 mRNA expression was
found to be comparable in the three breast epithelial cell
lines, whilst VDR, HDAC4 and HDAC7 gene expression
was highest in MDA-MB453 cells (Figure S3A).
Depending on the cell line small inhibitory (si) RNA
against VDR reduced mRNA expression of its target gene
by approximately 70%, NCoR1 siRNA 50–85%, HDAC3
siRNA 80–90%, HDAC4 siRNA 75–90%, HDAC6
siRNA 70–80% and HDAC7 siRNA 40–60%
(Figure S3B). The downregulation by RNA silencing
was also manifested at the protein level of the targeted
genes (data not shown). Moreover, the eﬀect of the
siRNAs on 1a,25(OH)2D3 signaling was tested by a 3h
stimulation of MCF-7 cells and measuring the modula-
tion of mRNA expression of the potently induced
1a,25(OH)2D3 target gene 24-hydroxylase (CYP24A1,
Figure S3C). The approximately 20-fold upregulation of
the CYP24A1 mRNA in MCF-7 cells was completely
abolished by VDR siRNA knockdown and increased by
50–150% by the siRNA knockdown of the genes HDAC3,
HDAC4 and HDAC7. In contrast, siRNA knockdown of
the NCoR1 and the HDAC6 gene both had no signiﬁcant
eﬀect on 1a,25(OH)2D3 signaling. For NCoR1 silencing
128 Nucleic Acids Research, 2008, Vol. 36, No. 1no eﬀect was measured, which may be related to low
eﬃcacy of siNCoR1 in MCF-7 cells.
The basal expression of the p18 gene was upregulated by
siRNA against all tested HDACs in the three cell lines and
with higher fold inductions in malignant cell lines
(Figure 4A, please note the diﬀerent scale for MCF-12A
cells). In non-malignant MCF-12A cells, NCoR1 or VDR
silencing increased p18 steady state mRNA expression
levels. The expression of p19 mRNA was promoted by
siRNA against NCoR1, HDAC3, HDAC4 and HDAC6 in
malignant cell lines and by siRNA against VDR in MCF-7
cells. On the contrary, in MCF-12A cells, p19 expression
was 2-fold reduced by siRNA against VDR and HDAC7.
Basal expression of the p21 gene was increased by
silencing NCoR1, HDAC4 and HDAC6 in malignant cell
lines and also by silencing VDR in MCF-7 cells. In MCF-
12A cells, siRNA against HDAC6 and HDAC7 uplifted
p21 expression. For p27 expression, the eﬀects of siRNA
were more variable amongst malignant cell lines. In both
malignant cell lines, silencing VDR increased p27 expres-
sion. Silencing NCoR1 and HDAC4 in MCF-7 cells or
HDAC6 and HDAC7 in MDA-MB453 cells also increased
p27 steady state basal expression levels. In contrast,
in MCF-12A cells, only silencing of HDAC6 promoted
p27 mRNA steady state mRNA expression levels.
The inhibition of the genes VDR, NCoR1 and the four
HDACs had also an impact on the ligand responsiveness
of the four CDKI genes (Figures 4B and S4). In MCF-7
cells the response of the p18 gene to TSA was upregulated
by siRNA against VDR and NCoR1 and downregulated
by siRNA against HDAC3 and HDAC4 (Figure 4B).
Moreover, the response of the p19 gene after stimulation
with a combination of TSA and 1a,25(OH)2D3 was
signiﬁcantly increased by NCoR1 siRNA. The response
of the p21 gene to TSA was promoted by NCoR1 siRNA
and the stimulation by 1a,25(OH)2D3 was enhanced by
HDAC3 and HDAC7 siRNA. Finally, both the respon-
siveness of the p27 gene to TSA and 1a,25(OH)2D3
treatments was increased by HDAC7 siRNA knockdown.
In MCF-12A cells siRNA had only minor eﬀects on ligand
responses (Figure S4A). As observed in MCF-7 cells
(Figure 4B), also in MDA-MB453 cells the response of
the p18 gene to TSA was upregulated by siRNA against
VDR and NCoR1 and downregulated by siRNA against
HDAC3 (Figure S4B). The induction of p21 by
1a,25(OH)2D3 was abolished with siRNA against either
VDR or NCoR1.
In summary, the most obvious results of these RNAi
experiments were that the basal expression of the p18 gene
was repressed in the three cell lines by the four HDACs.
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Figure 4. HDACs and NCoR1 have opposite eﬀects on the inducibility of CDKI genes. MCF-12A, MCF-7 and MDA-MB453 cells were ﬁrst
transfected for 48h with siRNA oligonucleotides against VDR, NCoR1, HDAC3, HDAC4, HDAC6 and HDAC7 and then either not treated (A)o r
MCF-7 cells were then stimulated, alone or in combination, with 15nM TSA, 10nM 1a,25(OH)2D3 and EtOH for 3h (B, for data of MCF-12A and
MDA-MB453 cells see Figure S3). Real-time quantitative PCR was used to determine the mRNA expression of the genes p18, p19, p21 and p27
relative to the control gene RPLP0 and fold inductions were calculated in reference to control siRNA (A) or vehicle (B). Columns indicate the means
of at least three independent cell treatments and the bars represent standard deviations. A two-tailed Student’s t-test was performed to determine the
signiﬁcance of the stimulation in reference to control siRNA (
P<0.05;
P<0.01;
P<0.001).
Nucleic Acids Research,2008, Vol. 36,No. 1 129In malignant breast epithelial cells inhibition of VDR
and NCoR1 had opposite eﬀects on the stimulation
of p18 gene expression than the block of HDAC3
and HDAC4, whilst in non-malignant cells, siRNA
inhibition had hardly any eﬀect on the responsiveness
of the CDKI genes. Response of the p21 gene to
1a,25(OH)2D3 was attenuated by HDAC3 and HDAC7
in MCF-7 cells, whereas removal of NCoR1 promoted
the basal expression level of the same gene and
consequently abolished 1a,25(OH)2D3 induction in
MDA-MB453 cells.
DISCUSSION
Anti-proliferative eﬀects both of HDAC inhibitors and
1a,25(OH)2D3 have been linked to changes in the
expression of CDKI genes (18,25). Based on this, we
studied this crossroad of epigenetic and VDR signaling in
three mammary cell lines with diﬀerential stage of
malignancy. For cell treatments we used a low concentra-
tion (15nM) of the HDAC inhibitor TSA, in order
to see additional or even co-operative eﬀects with
1a,25(OH)2D3. Although this concentration is suﬃcient
to inhibit HDACs in both malignant cell lines used in this
study (26), we observed an anti-proliferative eﬀect of TSA
alone only in MCF-7 cells. In contrast, all three cell lines
were inhibited in their growth by 1a,25(OH)2D3. The anti-
proliferative eﬀect in the two malignant cell lines is due to
growth arrest in the G1/G0 phase and not based on the
induction of apoptosis. Importantly, in MCF-7 cells, we
even observed a co-operative anti-proliferative eﬀect
between the two compounds, as already previously
observed by Banwell and co-workers for the MDA-
MB231 malignant mammary cell line (27).
Expression proﬁling of the four CDKI genes p18, p19,
p21 and p27, which are all expressed in the three cell lines,
indicated that the TSA-induced growth arrest could be
mediated by the induction of INK4 gene family members.
In particular, p18 seems to be the most sensitive and
rapidly responding TSA target gene with highest response
in MCF-7 cells. This is in accordance with the cell-speciﬁc
proﬁle of anti-proliferative eﬀects in the tested cell lines.
Further support of the idea that the anti-proliferative
eﬀect of TSA is mediated by upregulation of p18 gene
expression, is provided by the observation that growth
inhibition by TSA was attenuated in mouse embryo
ﬁbroblasts lacking p18 (11). However, in contrast to
previous observations (13), in the breast epithelial cells
tested here, p21 does not respond as quickly and to a lesser
extent, since we did not observe any mRNA induction
earlier than after 6h of stimulation. Nevertheless, in both
malignant mammary cell lines TSA acts co-operatively
with 1a,25(OH)2D3 on the induction of the p21 gene.
General acetylation of histone H4 and acetylation
of histone H3 at lysine 14 are associated with active
chromatin (28). We observed that the level of histone
modiﬁcations on the TSS regions of the genes p18, p19 and
p21 is higher in non-malignant MCF-12A cells than in the
two malignant mammary cell lines. For p18 and p21 this
nicely correlates with the basal mRNA expression of these
genes, but there must be additional mechanisms that
mediate the high basal p19 expression in MDA-MB453
cells. Interestingly, TSA is able to enhance the level of
these histone modiﬁcations not only on the p18, p19 and
p21 TSS regions but also on the VDR-associated regions
of the p21 promoter. However, HDAC inhibition did not
induce acetylation on the p27-TSS as already reported
previously (13). This indicates a broad but not completely
unspeciﬁc eﬀect of TSA on gene activation. The TSA
sensitive TSS regions show as a common feature a high
basal association with HDAC3 and in most cases also
with NCoR1.
In the three tested cell lines there is a consistent,
statistically signiﬁcant upregulation of the p21 gene by
1a,25(OH)2D3, which supports the idea that this gene is
critical for the anti-proliferative eﬀect of 1a,25(OH)2D3.
In this study, TSA did not induce p21 expression contrary
to previous reports (29,30). This may be due to diﬀerences
in the experimental design. For example, the concentra-
tion and time of TSA exposure used in our experiments
were substantially smaller than those used by others,
which were 7–17h treatment with 25–100ng/ml (29,30).
Previously, we have identiﬁed three VDR-associated
regions by ChIP scanning of the p21 promoter (17) and we
used these regions as an example of 1a,25(OH)2D3-
responding chromatin. Here we demonstrate that
1a,25(OH)2D3, but not TSA, induces looping of the two
more distal regions at positions 4.5kB and 6.9kB.
However, we could not detect DNA looping of the more
proximal region at position 2.3kB, although on the level
of histone acetylation this region responded well to both
TSA and 1a,25(OH)2D3 and re-ChIP assays showed
1a,25(OH)2D3-dependent VDR–Pol II complex forma-
tion. On all three p21 promoter regions both TSA and
1a,25(OH)2D3 abolishes the association of VDR with
HDAC7 (and to some extent also that with HDAC4
and HDAC6). In MCF-7 cells, HDAC3 and HDAC7
attenuate the response of the p21 gene to 1a,25(OH)2D3.
These cells also have the lowest response of their p21 gene
to 1a,25(OH)2D3 and the highest ratio of HDAC3 to
VDR expression.
A previously described model involving the progester-
one receptor, proposed that HDAC3 quenches the
induction by the ligand and drives the return to the
basal state (31) and our data agrees in general with this.
When 1a,25(OH)2D3 is combined with TSA or when
either HDAC3 or HDAC7 gene expression is silenced
in 1a,25(OH)2D3-treated cells, the activation of p21
transcription is prolonged and more mRNA can accumu-
late. This attenuation of the 1a,25(OH)2D3 response by
HDACs is not restricted to the p21 gene, since the
induction of another 1a,25(OH)2D3 induced gene,
CYP24A1, is also enhanced by silencing either HDAC3,
HDAC4 or HDAC7. Previously, HDAC3 has been linked
to regulation by nuclear receptors via NCoR1/SMRT
co-repressor complexes (32), but in a recent study,
HDAC3 and HDAC4 were shown to bind nuclear
receptors also directly and independently of co-repressor
(33). HDAC7 has been found to bind an ERa a target
gene in the presence of the ligand (34), analogously to its
role in quenching nuclear receptor ligand response in
130 Nucleic Acids Research, 2008, Vol. 36, No. 1addition to putative basal repression by un-liganded
nuclear receptors. Silencing HDAC expression may also
have other, more indirect eﬀects, e.g. via regulation of
expression of other co-factors, but this cannot explain the
fast combinatorial eﬀects of by TSA and 1a,25(OH)2D3
on the regulation of CDKI genes. The regulation
of deacetylation activity of HDAC3 and class II HDACs
by stimulus-dependent nucleocytoplasmic shuttling (3)
enables an additional layer for cell-speciﬁc ﬁne-tuning of
nuclear receptor response.
RNAi experiments indicated that both NCoR1 and
un-liganded VDR appear to be repressors of the basal
expression of CDKI genes. Elevated NCoR1 levels have
been linked with suppressed target gene response to
1a,25(OH)2D3 both in mammary cell lines and in primary
breast cancer tumors (35), but paradoxically, we found
that silencing the NCoR1 gene transcriptionally, abolished
the induction of the p21 gene by 1a,25(OH)2D3. Our
results suggest that 1a,25(OH)2D3 is unable to induce the
p21 gene in the absence of NCoR1, since release from
repression by VDR–NCoR1 complexes (either by ligand
application or by inhibiting NCoR1 expression) raises the
basal expression level to the same extent. Therefore, one
can assume that the optimal level of NCoR1 expression
is essential to the ligand responsiveness.
As expected, silencing HDACs decreased mRNA
induction by TSA. However, it is still surprising that
silencing of either HDAC3 or HDAC4 alone already
reduced the TSA induction of the p18 gene by 50%. This
suggests that both HDACs have a central role in
mediating the eﬀects of HDAC inhibitors on the regula-
tion of the p18 gene. The strong overlap between genes
inducible with TSA (either 15 or 100nM) or by the
inhibition of HDAC3 in the three tested cell lines further
supports the idea that HDAC3 is the main target of TSA
in regulating CDKI genes. Since HDAC3 is ubiquitously
expressed, knockdown of HDAC3 should have broad
and tissue-unspeciﬁc consequences to the response to
1a,25(OH)2D3 and TSA. On the other hand, silencing
either HDAC4 or HDAC6 induced the expression of
CDKI genes more broadly, independently of their
responsiveness to TSA. Additionally, according to our
ChIP experiments, HDAC4 and HDAC6 were not
associated with the target gene’s TSS regions to an
extent that could explain induction upon their removal.
This suggests more complex processes than a swift
increase in histone acetylation. For example, the role of
HDAC6 in proteasomal degradation of misfolded pro-
teins may contribute to upregulation of CDKI genes upon
knockdown of HDAC6 (7).
In conclusion, our studies suggest an overlap of the
anti-proliferative eﬀects of the HDAC inhibitor TSA
and the nuclear receptor ligand 1a,25(OH)2D3 in mam-
mary cell lines. Transcriptional induction by both
TSA and 1a,25(OH)2D3 is strongly linked to HDAC
and NCoR1 but with opposite consequences, they
act through diﬀerent pathways. HDACs, especially
HDAC3, are rate-limiting factors in the termination of
ligand-induced transcription, where NCoR1 is not essen-
tial, whereas NCoR1 is rate limiting in transcriptional
repression aﬀorded by un-liganded VDR, while active
HDACs are not essential. The attenuation of the
1a,25(OH)2D3 response by HDACs or of the TSA
response by NCoR1 can be overcome by combing
these substances to achieve maximal induction of anti-
proliferative target genes.
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